Drawing on practical experience, the authors examine key questions and answers about various aspects relating to the enhanced approach for analytical procedure lifecycle management.
Andy Rignall
Advertisement
Andy Rignall is product technical director at AstraZeneca.
Articles by Andy Rignall
Three hypothetical analytical target profiles (ATPs) are provided, reflecting the current thinking of the the European Federation of Pharmaceutical Industries and Associations Analytical Lifecycle Management Team.
Advertisement
Latest Updated Articles
Analytical Procedure Lifecycle Management: Current Status and OpportunitiesPublished: December 2nd 2018 | Updated:
Three Examples of Hypothetical ATPsPublished: December 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program
2
Leveraging AI/ML to Reduce Risk in Drug Development: Part One
3
New Targets for Clinical Trials in the European Union
4
Nuclear Waste to Medicine: The UK’s Lead-212 Strategy for Cancer Care
5
